

Elecsys N-MID Osteocalcin

REF			SYSTEM
12149133160	12149133501	100	cobas e 411 cobas e 601 cobas e 602

English

For use in the USA only

System information

For **cobas e 411** analyzer: test number 660

For **cobas e 601** and **cobas e 602** analyzers: Application Code Number 122

Intended use

Immunoassay for the in vitro quantitative determination of N-MID osteocalcin in human serum and plasma. The determination of osteocalcin, an indication of human bone formation and osteoblastic activity, may be useful as an aid in the management of postmenopausal osteoporosis.

The electrochemiluminescence immunoassay "ECLIA" is intended for use on **cobas e** immunoassay analyzers.

Summary

Osteocalcin, the most important non-collagen protein in bone matrix, is a bone-specific, calcium-binding protein which is dependent on vitamin K. It contains 49 amino acids and has a molecular weight of approximately 5800 Da. It contains up to 3 γ-carboxyglutamic acid residues (bone-GLA-protein, BGP). During bone synthesis osteocalcin is produced by the osteoblasts. Its production is dependent upon vitamin K (formation of γ-carboxyglutamic acid residues) and is stimulated by vitamin D3. After release from the osteoblasts, osteocalcin is not only assimilated into the bone matrix but also secreted into the blood stream. Accordingly, the serum (plasma) osteocalcin level is related to the rate of bone turnover and its measurement is useful in disorders of bone metabolism, e.g. osteoporosis in particular, but also in primary and secondary hyperparathyroidism.^{1,2,3,4,5} Osteocalcin is therefore termed a bone turnover marker and is used for this purpose. By means of osteocalcin measurements it is possible to monitor therapy with antiresorptive agents (bisphosphonates or hormone replacement therapy, HRT) in, for example, patients with osteoporosis.^{6,7,8} Both intact osteocalcin (amino acids 1-49) and the large N-MID fragment (amino acids 1-43) occur in blood. Intact osteocalcin is unstable due to protease cleavage between amino acids 43 and 44. The N-MID-fragment resulting from cleavage is considerably more stable.^{4,9} The Elecsys N-MID Osteocalcin assay uses 2 monoclonal antibodies specifically directed against epitopes on the N-MID-fragment and the N-terminal-fragment. The assay hence detects the stable N-MID-fragment as well as the (still) intact osteocalcin. The test is non-dependent on the unstable C-terminal-fragment (amino acids 43-49) of the osteocalcin molecule and thus ensures constant measurement results under routine conditions in the laboratory.¹⁰

Test principle

Sandwich principle. Total duration of assay: 18 minutes.

- 1st incubation: 20 µL of sample, a biotinylated monoclonal N-MID osteocalcin-specific antibody, and a monoclonal N-MID osteocalcin-specific antibody labeled with a ruthenium complex^{a)} react to form a sandwich complex.
- 2nd incubation: After addition of streptavidin-coated microparticles, the complex becomes bound to the solid phase via interaction of biotin and streptavidin.
- The reaction mixture is aspirated into the measuring cell where the microparticles are magnetically captured onto the surface of the electrode. Unbound substances are then removed with ProCell/ProCell M. Application of a voltage to the electrode then induces chemiluminescent emission which is measured by a photomultiplier.
- Results are determined via a calibration curve which is instrument-specifically generated by 2-point calibration and a master curve provided via the reagent barcode or e-barcode.

a) Tris(2,2'-bipyridyl)ruthenium(II)-complex (Ru(bpy)₃²⁺)

Reagents - working solutions

The reagent rackpack is labeled as OSTEOC.

- M Streptavidin-coated microparticles (transparent cap), 1 bottle, 6.5 mL: Streptavidin-coated microparticles 0.72 mg/mL; preservative.
- R1 Anti-N-MID Osteocalcin-Ab~biotin (gray cap), 1 bottle, 10 mL: Biotinylated monoclonal anti-N-MID Osteocalcin antibody (mouse) 1.5 mg/L; phosphate buffer 100 mmol/L, pH 6.0; preservative.
- R2 Anti-N-MID Osteocalcin-Ab~Ru(bpy)₃²⁺ (black cap), 1 bottle, 10 mL: Monoclonal anti-N-MID Osteocalcin antibody (mouse) labeled with ruthenium complex 1.3 mg/L; phosphate buffer 100 mmol/L, pH 6.0; preservative.

Precautions and warnings

For in vitro diagnostic use for healthcare professionals. Exercise the normal precautions required for handling all laboratory reagents.

Infectious or microbial waste:

Warning: handle waste as potentially biohazardous material. Dispose of waste according to accepted laboratory instructions and procedures.

Environmental hazards:

Apply all relevant local disposal regulations to determine the safe disposal.

Safety data sheet available for professional user on request.

This kit contains components classified as follows in accordance with the Regulation (EC) No. 1272/2008:



Warning

H317 May cause an allergic skin reaction.

Prevention:

P261 Avoid breathing mist or vapours.

P272 Contaminated work clothing should not be allowed out of the workplace.

P280 Wear protective gloves.

Response:

P333 + P313 If skin irritation or rash occurs: Get medical advice/attention.

P362 + P364 Take off contaminated clothing and wash it before reuse.

Disposal:

P501 Dispose of contents/container to an approved waste disposal plant.

Hazardous components:

- 2-methyl-2H-isothiazol-3-one hydrochloride

Product safety labeling follows EU GHS guidance.

Contact phone: 1-800-428-2336

Avoid foam formation in all reagents and sample types (specimens, calibrators and controls).

Reagent handling

The reagents in the kit have been assembled into a ready-for-use unit that cannot be separated.

All information required for correct operation is read in from the respective reagent barcodes.

Elecsys N-MID Osteocalcin



Storage and stability

Store at 2-8 °C.

Do not freeze.

Store the Elecsys reagent kit **upright** in order to ensure complete availability of the microparticles during automatic mixing prior to use.

Stability:	
unopened at 2-8 °C	up to the stated expiration date
after opening at 2-8 °C	12 weeks
on the analyzers	8 weeks

Specimen collection and preparation

Only the specimens listed below were tested and found acceptable.

Serum collected using standard sampling tubes.

Li-heparin, K₂-EDTA and K₃-EDTA plasma.

Criterion: Method comparison serum versus plasma, slope 0.9-1.10 + intercept \pm 1 ng/mL + coefficient of correlation \geq 0.95.

Note: Avoid hemolysis! Erythrocytes contain proteases which degrade osteocalcin. It is recommended that blood be centrifuged immediately.

Stability of serum and heparinized plasma: 8 hours at 15-25 °C, 3 days at 2-8 °C, 3 months at -20 °C (\pm 5 °C). Freeze once only.

Stability of EDTA-plasma: 2 days at 15-25 °C, 3 days at 2-8 °C, 3 months at -20 °C (\pm 5 °C). Freeze only once.

The sample types listed were tested with a selection of sample collection tubes that were commercially available at the time of testing, i.e. not all available tubes of all manufacturers were tested. Sample collection systems from various manufacturers may contain differing materials which could affect the test results in some cases. When processing samples in primary tubes (sample collection systems), follow the instructions of the tube manufacturer.

Centrifuge samples containing precipitates before performing the assay.

Do not use heat-inactivated samples.

Do not use samples and controls stabilized with azide.

Ensure the samples, calibrators and controls are at 20-25 °C prior to measurement.

Due to possible evaporation effects, samples, calibrators and controls on the analyzers should be analyzed/measured within 2 hours.

Sample stability claims were established by experimental data by the manufacturer or based on reference literature and only for the temperatures/time frames as stated in the Method Sheet. It is the responsibility of the individual laboratory to use all available references and/or its own studies to determine specific stability criteria for its laboratory.

Materials provided

See "Reagents – working solutions" section for reagents.

Materials required (but not provided)

- [REF] 1197211122, N-MID Osteocalcin CalSet, for 4 x 1.0 mL
- [REF] 05618860160, PreciControl Varia, for 6 x 3.0 mL
- [REF] 03183971122, Diluent Universal, 2 x 36 mL sample diluent
- General laboratory equipment

cobas e analyzer

Additional materials for **cobas e 411** analyzer:

- [REF] 11662988122, ProCell, 6 x 380 mL system buffer
- [REF] 11662970122, CleanCell, 6 x 380 mL measuring cell cleaning solution
- [REF] 11930346122, Elecsys SysWash, 1 x 500 mL washwater additive
- [REF] 11933159001, Adapter for SysClean
- [REF] 11706802001, AssayCup, 60 x 60 reaction cups
- [REF] 11706799001, AssayTip, 30 x 120 pipette tips
- [REF] 11800507001, Clean-Liner

Additional materials for **cobas e 601** and **cobas e 602** analyzers:

- [REF] 04880340190, ProCell M, 2 x 2 L system buffer

- [REF] 04880293190, CleanCell M, 2 x 2 L measuring cell cleaning solution
- [REF] 03023141001, PC/CC-Cups, 12 cups to prewarm ProCell M and CleanCell M before use
- [REF] 03005712190, ProbeWash M, 12 x 70 mL cleaning solution for run finalization and rinsing during reagent change
- [REF] 03004899190, PreClean M, 5 x 600 mL detection cleaning solution
- [REF] 12102137001, AssayTip/AssayCup, 48 magazines x 84 reaction cups or pipette tips, waste bags
- [REF] 03023150001, WasteLiner, waste bags
- [REF] 03027651001, SysClean Adapter M

Additional materials for all analyzers:

- [REF] 11298500160, ISE Cleaning Solution/Elecsys SysClean, 5 x 100 mL system cleaning solution

Assay

For optimum performance of the assay follow the directions given in this document for the analyzer concerned. Refer to the appropriate operator's manual for analyzer-specific assay instructions.

Resuspension of the microparticles takes place automatically prior to use. Read in the test-specific parameters via the reagent barcode. If in exceptional cases the barcode cannot be read, enter the 15-digit sequence of numbers.

cobas e 601 and **cobas e 602** analyzers: PreClean M solution is necessary.

Bring the cooled reagents to approximately 20 °C and place on the reagent disk (20 °C) of the analyzer. Avoid foam formation. The system automatically regulates the temperature of the reagents and the opening/closing of the bottles.

Calibration

Traceability: This method has been standardized against in-house reference standards: osteocalcin in analyte-free human serum matrix.

Every Elecsys reagent set has a barcoded label containing specific information for calibration of the particular reagent lot. The predefined master curve is adapted to the analyzer using the relevant CalSet.

Calibration frequency: Calibration must be performed once per reagent lot using fresh reagent (i.e. not more than 24 hours since the reagent kit was registered on the analyzer). Renewed calibration is recommended as follows:

Calibration interval may be extended based on acceptable verification of calibration by the laboratory.

- every 12 weeks when using the same reagent lot
- every 7 days (when using the same reagent kit on the analyzer)
- as required: e.g. quality control findings outside the defined limits

Quality control

Use PreciControl Varia or other suitable controls for routine quality control procedures.

Controls for the various concentration ranges should be run individually at least once every 24 hours when the test is in use, once per reagent kit, and following each calibration.

The control intervals and limits should be adapted to each laboratory's individual requirements. Values obtained should fall within the defined limits. Each laboratory should establish corrective measures to be taken if values fall outside the defined limits.

If necessary, repeat the measurement of the samples concerned.

Follow the applicable government regulations and local guidelines for quality control.

Calculation

The analyzer automatically calculates the analyte concentration of each sample either in ng/mL or μ g/L.

Limitations - interference

The effect of the following endogenous substances and pharmaceutical compounds on assay performance was tested. Interferences were tested up to the listed concentrations and no impact on results was observed.

Endogenous substances

Compound	Concentration tested
Bilirubin	≤ 1112 μmol/L or ≤ 65 mg/dL
Intralipid	≤ 1500 mg/dL
Biotin	≤ 205 nmol/L or ≤ 50 ng/mL
Rheumatoid factors	≤ 2200 IU/mL

Criterion: Recovery within ± 2 ng/mL of initial value for samples ≤ 20 ng/mL and within ± 10 % of initial value for samples > 20 ng/mL.

Hemolysis interferes. Erythrocytes contain proteases which degrade osteocalcin.

Samples should not be taken from patients receiving therapy with high biotin doses (i.e. > 5 mg/day) until at least 8 hours following the last biotin administration.

There is no high-dose hook effect at N-MID osteocalcin concentrations up to 4200 ng/mL.

In vitro tests were performed on 16 commonly used pharmaceuticals. No interference with the assay was found.

In rare cases, interference due to extremely high titers of antibodies to analyte-specific antibodies, streptavidin or ruthenium can occur. These effects are minimized by suitable test design.

For diagnostic purposes, the results should always be assessed in conjunction with the patient's medical history, clinical examination and other findings.

Limits and ranges

Measuring range

0.500-300 ng/mL (defined by the lower detection limit and the maximum of the master curve). Values below the lower detection limit are reported as < 0.500 ng/mL. Values above the measuring range are reported as > 300 ng/mL (or up to 1500 ng/mL for 5-fold diluted samples).

Lower limits of measurement

Lower detection limit of the test

Lower detection limit: < 0.500 ng/mL.

The Lower Detection Limit represents the lowest measurable analyte level that can be distinguished from zero. It is calculated as the value lying two standard deviations above that of the lowest standard (master calibrator, standard 1 + 2 SD, repeatability study, n = 21).

Dilution

Samples with N-MID osteocalcin concentrations above the measuring range can be diluted with Diluent Universal. The recommended dilution is 1:5 (either automatically by the analyzer or manually). The concentration of the diluted sample must be > 50 ng/mL.

After manual dilution, multiply the result by the dilution factor.

After dilution by the analyzers, the software automatically takes the dilution into account when calculating the sample concentration.

Expected values

The reference ranges are test-dependent. Completed studies with the Elecsys N-MID Osteocalcin assay have revealed the following ranges in ng/mL:

	Number	N-MID Osteocalcin	
		Median (ng/mL)	5-95 th Percentile
Healthy women			
• Premenopausal, > 21 yrs.			
Caucasian	133	18.5	9.7-35.1
Afro-American	160	16.3	7.6-30.7
• Postmenopausal, w/o diagnosed osteoporosis			
Caucasian	141	17.5	7.3-37.8
Afro-American	160	18.1	8.4-38.5
Osteoporosis patients	103	29.1	17.3-48.6

	Number	N-MID Osteocalcin	
		Median (ng/mL)	5-95 th Percentile
Healthy men			
• 30-50 yrs.			
Caucasian	130	22.9	10.2-36.7
Afro-American	151	18.3	8.4-33.6
• 51-70 yrs.			
Caucasian	117	18.5	10.8-31.1
Afro-American	117	17.6	9.9-35.6
• > 70 yrs.			
Caucasian	25	15.9	Percentile range not reliable for sample size less than 110
Afro-American	13	14.9	

In patients with renal failure the osteocalcin values can be elevated, both directly, due to impaired clearance and indirectly, due to renal osteodystrophy.¹¹

Each laboratory should investigate the transferability of the expected values to its own patient population and if necessary determine its own reference ranges.

Specific performance data

Representative performance data on the analyzers are given below. Results obtained in individual laboratories may differ.

Precision

Precision was determined using Elecsys reagents, pooled human sera and controls in a protocol (EP5-A2) of the CLSI (Clinical and Laboratory Standards Institute): 2 runs per day in duplicate each for 21 days (n = 84). The following results were obtained:

cobas e 411 analyzers					
Sample	Mean ng/mL	Repeatability		Intermediate precision	
		SD ng/mL	CV %	SD ng/mL	CV %
Human serum 1	6.01	0.085	1.4	0.186	3.1
Human serum 2	12.2	0.135	1.1	0.373	3.1
Human serum 3	35.6	0.601	1.7	1.06	3.0
Human serum 4	169	3.12	1.9	5.56	3.3
Human serum 5	8.11	0.091	1.1	0.159	2.0
PreciControl Varia 1	19.3	0.164	0.9	0.267	1.4
PreciControl Varia 2	93.2	1.01	1.1	1.65	1.8

cobas e 601 and cobas e 602 analyzers					
Sample	Mean ng/mL	Repeatability		Intermediate precision	
		SD ng/mL	CV %	SD ng/mL	CV %
Human serum 1	6.11	0.056	0.9	0.120	2.0
Human serum 2	12.0	0.126	1.1	0.240	2.0
Human serum 3	34.5	0.361	1.1	0.677	2.0
Human serum 4	160	2.03	1.3	3.65	2.3
Human serum 5	7.49	0.066	0.9	0.107	1.4
PreciControl Varia 1	17.9	0.166	0.9	0.207	1.2
PreciControl Varia 2	85.9	0.755	0.9	1.12	1.3

Elecsys N-MID Osteocalcin

Method comparison

A comparison of the Elecsys N-MID Osteocalcin assay (y) with a commercially available N-MID osteocalcin test (x) using clinical samples gave the following correlations (ng/mL):

Number of samples measured: 48

Passing/Bablok¹²

$$y = 1.31x + 2.0$$

$$r = 0.966$$

$$md(68) = 0.816$$

The sample concentrations were between 2.58 and 49.8 ng/mL.

Analytical specificity

For the monoclonal antibodies used, the following cross-reactivities were found:

No cross-reactivity detectable for β -CrossLaps, parathyroid hormone, and bone-specific alkaline phosphatase.

Clinical Data

Elecsys N-MID Osteocalcin assay and a commercially available N-MID osteocalcin test were used to measure retrospective samples from 57 subjects participating in a clinical study involving two Calcitonin treatments over six months.

Samples were taken from patients at weeks 0, 4, 12 and 24. The method comparison is presented to describe the linear regression. Number of samples measured: 228


Passing/Bablok¹²

$$y = 1.12x + 4.4$$


$$r = 0.922$$

$$md(68) = 1.337$$

The sample concentrations were between 9.19 and 93.4 ng/mL.



A box and whiskers plot for the clinical study population is also presented below. A clinical population of 1147 reference cohort individuals and 103 osteoporotic cohort individuals (pretreatment) is depicted.



References

- Rosenquist C, Qvist P, Bjarnason N, et al. Measurement of a More Stable Region of Osteocalcin in Serum by ELISA with Two Monoclonal Antibodies. *Clin Chem* 1995;41(10):1439-1445.
- Delmas PD, Wahner HW, Mann KG, et al. Assessment of bone turnover in postmenopausal osteoporosis by measurement of serum bone Gla-protein. *J Lab Clin Med* 1983;102(4):470-476.
- Delmas PD, Wilson DM, Mann KG, et al. Effects of Renal Function on Plasma Levels of Bone Gla Protein. *J Clin Endocrinol Metab* 1983;57(5):1028-1030.
- Garnero P, Grimaux M, Seguin P, et al. Characterisation of Immunoreactive Forms of Human Osteocalcin Generated In Vivo and In Vitro. *J Bone Miner Res* 1994;9(2):255-264.
- Epstein S. Bone-Derived Proteins. *Trends Endocrinol Metab* 1989;1:9-14.
- Chen J-T, Hosoda K, Hasumi K, et al. Serum N-Terminal Osteocalcin is a Good Indicator for Estimating Responders to Hormone Replacement Therapy in Postmenopausal Women. *J Bone Miner Res* 1996;11(11):1784-1792.
- Ravn P, Christensen JO, Baumann M, et al. Changes in Biochemical Markers and Bone Mass After Withdrawal of Ibandronate Treatment: Prediction of Bone Mass Changes During Treatment. *Bone* 1998;22(5):559-564.
- Brown JP, Malaval L, Chapuy MC, et al. Serum bone GLA protein: A specific marker for bone formation in postmenopausal osteoporosis. *Lancet* 1984;1091-1093.
- Gundberg CM. Biology, Physiology, and Clinical Chemistry of Osteocalcin. *J Clin Ligand Assay* 1998;21(2):128-138.
- Garnero P, Delmas PD. New Developments in Biological Markers for Osteoporosis. *Calcif Tissue Int* 1996;59(1):2-9.
- Masters PW, Jones RG, Purves DA, et al. Commercial assays for serum osteocalcin give clinically discordant results. *Clin Chem* 1994;40(3):358-363.
- Bablok W, Passing H, Bender R, et al. A general regression procedure for method transformation. Application of linear regression procedures for method comparison studies in clinical chemistry, Part III. *J Clin Chem Clin Biochem* 1988 Nov;26(11):783-790.

For further information, please refer to the appropriate user guide or operator's manual for the analyzer concerned, the respective application sheets and the Method Sheets of all necessary components (if available in your country).

Any serious incident that has occurred in relation to the device shall be reported to the manufacturer and the competent authority of the Member State in which the user and/or the patient is established.

Symbols

Roche Diagnostics uses the following symbols and signs in addition to those listed in the ISO 15223-1 standard (for USA: see navifyportal.roche.com for definition of symbols used):

Elecsys N-MID Osteocalcin

CONTENT	Contents of kit
SYSTEM	Analyzers/Instruments on which reagents can be used
REAGENT	Reagent
CALIBRATOR	Calibrator
	Volume for reconstitution
GTIN	Global Trade Item Number

Rx only For USA: Caution: Federal law restricts this device to sale by or on the order of a physician.

FOR US CUSTOMERS ONLY: LIMITED WARRANTY

Roche Diagnostics warrants that this product will meet the specifications stated in the labeling when used in accordance with such labeling and will be free from defects in material and workmanship until the expiration date printed on the label. THIS LIMITED WARRANTY IS IN LIEU OF ANY OTHER WARRANTY, EXPRESS OR IMPLIED, INCLUDING ANY IMPLIED WARRANTY OF MERCHANTABILITY OR FITNESS FOR PARTICULAR PURPOSE. IN NO EVENT SHALL ROCHE DIAGNOSTICS BE LIABLE FOR INCIDENTAL, INDIRECT, SPECIAL OR CONSEQUENTIAL DAMAGES.

COBAS, NAVIFY, ELECSYS and PRECICONTROL are trademarks of Roche. INTRALIPID is a trademark of Fresenius Kabi AB.

All other product names and trademarks are the property of their respective owners.

Additions, deletions or changes are indicated by a change bar in the margin.

© 2025, Roche Diagnostics

For USA: Rx only



Roche Diagnostics GmbH
Sandhofer Strasse 116
68305 Mannheim, Germany
www.roche.com

+800 5505 6606



Roche Diagnostics
9115 Hague Road
Indianapolis, IN 46256, USA

+1 800 4282336

